Health organizations disagree on estradiol patch availability as surging menopause treatment demand fuels global shortages. While the American Society of Health-System Pharmacists has designated a shortage since January 2026, the FDA refuses to declare an official shortage, claiming supply nearly doubled despite local pharmacy strain. Meanwhile, over 2 million UK women and thousands of US patients face severe prescription fulfillment barriers.
Disagreement over US estradiol patch shortages
- ▪The U.S. Food and Drug Administration stated on September 3, 2026 that estradiol patch supply nearly doubled over the prior year and products remain available.
- ▪The U.S. Food and Drug Administration has not officially declared a shortage of estradiol patches or listed them in its drug shortage database.
- ▪Patient advocacy groups are pressing the U.S. Food and Drug Administration to officially declare a shortage of estradiol patches.
- ▪The American Society of Health-System Pharmacists has listed certain estradiol patch products in shortage since January 30, 2026.
Patient struggles with US patch supply
- ▪Pittsburgh-area pharmacists reported in July 2026 that estradiol patch supply constraints had lasted six to eight months, forcing patients to travel up to 40 minutes.
- ▪Almost half of women with estradiol patch prescriptions struggled to fill them, according to a May 2026 survey by virtual care company Midi Health.
Reasons for rising demand
- ▪An OB-GYN told NBC News that prescriptions had been rising before November 2025 as menopause care became more openly discussed.
- ▪The U.S. Food and Drug Administration attributed rising estradiol patch demand partly to its November 2025 decision to remove boxed warnings from menopausal hormone therapy products.
Rising demand for HRT in the UK
- ▪Hormone replacement therapy prescription use in the UK increases by more than 10% year over year, according to sexual health consultant Paula Briggs.
- ▪Almost 2 million women in England aged 40 and above were prescribed hormone replacement therapy for menopause symptoms in 2025-26, according to the NHS Business Services Authority.
Estradiol patch shortages in the UK
- ▪National Pharmacy Association board member Sehar Shahid stated that Estradot shortages represent the second longest-running individual medicine shortage in the UK.
- ▪Shortages of Estradot HRT patches in the UK began in December 2024 and are expected to persist until January.
- ▪FemSeven Conti transdermal patches are out of stock in the UK until late November 2026, according to a UK Department of Health and Social Care notification.
Managing shortages with alternative HRT patches
- ▪Consultant Paula Briggs stated that switching to alternative HRT patches with an identical estradiol dose maintains symptom control despite differing progestogens.
- ▪Alternative UK transdermal patches containing estradiol and norethisterone include Evorel Conti, Estradot Conti 30/95, and Estradot Conti 40/130.
Advice for affected patients
- ▪Curely pharmacist Sobia Qasim advised patients against leaving hormone replacement therapy patches on longer than prescribed, cutting patches, or borrowing treatments from others.
- ▪National Pharmacy Association board member Sehar Shahid advised patients experiencing disruption to their hormone replacement therapy regime to speak to their clinician.
Story comments
Loading comments…